Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

PURPOSE: This study sought to establish whether functional analysis of the ATM-p53-p21 pathway adds to the information provided by currently available prognostic factors in patients with chronic lymphocytic leukemia (CLL) requiring frontline chemotherapy. EXPERIMENTAL DESIGN: Cryopreserved blood mon...

Full description

Bibliographic Details
Main Authors:	Lin, K, Adamson, J, Johnson, G, Carter, A, Oates, M, Wade, R, Richards, S, Gonzalez, D, Matutes, E, Dearden, C, Oscier, D, Catovsky, D, Pettitt, A
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
by: Gonzalez, D, et al.
Published: (2011)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
by: Oscier, D, et al.
Published: (2010)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
by: Gonzalez, D, et al.
Published: (2008)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

Quality of life in the LRF CLL4 trial.
by: Else, M, et al.
Published: (2005)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
by: Matutes, E, et al.
Published: (2013)

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
by: Matutes, E, et al.
Published: (2013)

Early results from LRF CLL4: A UK multicenter randomized trial
by: Catovsky, D, et al.
Published: (2005)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2006)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
by: Else, M, et al.
Published: (2012)

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.
by: Else, M, et al.
Published: (2008)

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.
by: Sellick, G, et al.
Published: (2008)

Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling.
by: Yunhai Luo, et al.
Published: (2014-07-01)

P599: RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL
by: B. L. Lampson, et al.
Published: (2022-06-01)

Gender as a prognostic factor in CLL. Biological pointers to the improved outcome of women.
by: Catovsky, D, et al.
Published: (2004)

Correction: Hypersensitivity of Primordial Germ Cells to Compromised Replication-Associated DNA Repair Involves ATM-p53-p21 Signaling
Published: (2014-09-01)

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
by: Pettitt, A, et al.
Published: (2012)

A novel ATM/TP53/p21-mediated checkpoint only activated by chronic γ-irradiation.
by: Lili Cao, et al.
Published: (2014-01-01)

Table of log21/p, p.log21/p and p.log21/p + (1-p).log21/1-p
Published: (2004)

Expression of p53 and p21 in bladder carcinoma of Iraqi patients
by: Rawaa Al Chalabi, et al.
Published: (2019-06-01)

p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
by: Villuendas, R, et al.
Published: (1997)

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
by: Marwan Kwok, et al.
Published: (2021-09-01)

Emerging treatment options for patients with p53-pathway-deficient CLL
by: Marisa J. L. Aitken, et al.
Published: (2019-12-01)

Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL
by: Antosz Halina, et al.
Published: (2010-04-01)

Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL.
by: Marzec-Kotarska Barbara, et al.
Published: (2011-04-01)

Comparison of ZAP-70, IgVH gene mutational status and CD38 in CLL patients requiring therapy: Preliminary report from the UKCLL IV trial.
by: Orchard, J, et al.
Published: (2003)

P637: FRONTLINE THERAPY CLL WITHOUT 17P DEL/P53 ABERRATIONS: SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS
by: G. Caridà, et al.
Published: (2022-06-01)

JNK inhibitor IX restrains pancreatic cancer through p53 and p21
by: Jingwei Shi, et al.
Published: (2022-12-01)

Inhibition of HIV early replication by the p53 and its downstream gene p21
by: Binshan Shi, et al.
Published: (2018-03-01)